The naevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by multiple developmental defects and cancer susceptibility, in particular to basal cell carcinomas (BCCs). Medulloblastomas, primitive neuroectodermal tumours (PNETs) arising in childhood, occur in about 3 ± 5% of NBCCS patients and a subset of PNETs was previously found with allelic imbalance at 9q22-q23, the region containing the gene for NBCCS (PTCH). We have analysed tumour DNA samples from 37 unrelated patients with sporadic PNETs and ®ve medulloblastoma cell lines for PTCH mutations using an exon-by-exon single strand conformation polymorphism assay. We found three missense mutations, which aect conserved residues in transmembrane domains of the gene product and in the extracellular loop implicated in binding sonic hedgehog, one 2 bp deletion and an exon skipping splice site mutation. Most mutations were associated with the absence of the wild-type allele and were found in tumours exhibiting loss of heterozygosity (LOH) at locī anking PTCH. The ®nding of LOH at 9q22-q23 in most mutated tumours while present in only three out of 26 tumours, in which a mutation was not identi®ed, implicates PTCH as the target gene in PNETs with LOH at 9q22-q23 and de®cient PTCH in the development of a subset of these tumours. Since all observed mutations were absent in the germ-line, a sporadic medulloblastoma developing as the ®rst symptom of NBCCS is likely to be a very uncommon event.
Introduction
The naevoid basal cell carcinoma (Gorlin) syndrome (NBCCS) is an autosomal dominant disorder characterized by multiple developmental defects and cancer susceptibility (Gorlin, 1987 (Gorlin, , 1995 . The gene for NBCCS, which was mapped to the chromosome region 9q22.3 by genetic linkage analysis (Gailani et al., 1992; Farndon et al., 1992 Farndon et al., , 1994 Reis et al., 1992; Wicking et al., 1994) , was recently identi®ed (Hahn et al., 1996a, b; Johnson et al., 1996) as a human homologue of Drosophila patched, a transmembrane glycoprotein involved in segment polarity patterning (Hooper and Scott, 1989) . The patched gene product was found to be a receptor for sonic hedgehog (shh, Stone et al., 1996; Marigo et al., 1996) and was implicated in transcriptional regulation of the WNT and TGF-b gene families. In vertebrates, signalling by shh is important for normal development of the central nervous system, as well as for the formation of distal limb structures and the spinal column (Hammerschmidt et al., 1997) .
The human gene, designated PTCH (formerly PTC), spans at least 23 exons corresponding to the physical distance of about 35 kb at 9q22.3. Mutations in the PTCH gene were identi®ed in a signi®cant proportion of NBCCS families (Hahn et al., 1996b; Unden et al., 1996; Chidambaram et al., 1996; Wicking et al., 1997) . Wild-type PTCH alleles or haplotypes were found to be absent in BCCs originating in NBCCS patients, consistent with PTCH acting as a tumour suppressor (Gailani et al., 1992; Unden et al., 1996; Levanat et al., 1996) . A signi®cant proportion of sporadic BCCs also contain PTCH mutations, suggesting that the gene may function as a gatekeeper in the commonest human cancer (Sidransky, 1996; Unden et al., 1996; .
Primitive neuroectodermal tumours (PNETs) account for about a quarter of all paediatric brain tumours. Medulloblastomas, usually arising in the midline of cerebellum, represent the most frequent PNETs. The survival rate of patients with medulloblastomas is still very poor (Merchant et al., 1996; David et al., 1997) . This has hampered genetic studies, with only occasional reports of multiple-case families, usually aected sib-pairs (Bickersta et al., 1967; Belamaric et al., 1969; Yamashita et al., 1975; Acqui et al., 1989; Hung et al., 1990; Scheurlen et al., 1996) . Unlike in more common tumours, reliable estimates of the relative risks for family members are not available. However, since medulloblastomas were estimated to occur in about 3 ± 5% of NBCCS patients (Evans et al., 1991) , and often early in childhood (Lacombe et al., 1990) , the germ-line mutations in the NBCCS gene may theoretically predispose to the development of a signi®cant number of sporadic PNETs. Moreover, allelic loss at 9q was found in desmoplastic PNETs (Scho®eld et al., 1995; Scheurlen et al., 1996) and other paediatric brain tumours (Albrecht et al., 1994; Blaeker et al., 1996) , suggesting the presence of a tumour suppressor. To test a possible involvement of PTCH in PNETs, we have analysed tumour DNA samples in unrelated Swedish patients for gene mutations using an exon scanning single strand conformation polymorph-ism assay (SSCP) and for loss of constitutional heterozygosity (LOH) in matched blood and tumour DNA.
Results

Identi®cation of PTCH mutations in medulloblastomas
The clinical and histopathological characterization of PNETs included in mutation screening is shown in Table 1 . The PTCH coding region was ampli®ed from 37 tumour DNA samples and ®ve medulloblastoma cell lines (PFSK1, D283Med, D324Med, D341Med and D425Med) using oligonucleotide primer pairs¯anking each exon. The PCR products were analysed on SSCP gels and those with altered mobility were sequenced. Mutations were found altogether in ®ve patients (Table  2 ) and they are shown in Figures 1 and 2 .
A single truncating mutation was revealed in tumour sample 21. This 2 bp deletion would be predicted to lead to premature termination of the translation product ( Figure 2a , b and Table 2 ). A splice site mutation in sample 19591, changing guanine to adenine at position +1 of intron 10 would be predicted to destroy this exon ± intron boundary and lead to exon skipping. The reverse transcription ± PCR analysis of RNA isolated from this tumour con®rmed a 156 bp deletion, corresponding to exon 10 (data not shown) and resulting in the removal of the second and third transmembrane domains.
Two missense mutations (M1139I and V1164I in Table 2 ) also changed residues predicted to lie within transmembrane domains (number 11 and 12, respectively), while the third missense mutation (patient PM2 in Table 2 ) would result in threonine to asparagine substitution in the large extracellular loop, which is required for shh binding (Marigo et al., 1996) . Thus, all ®ve identi®ed mutations would be predicted to result in a de®cient gene product.
While the patient 19591 with the splice site mutation in his tumour developed widespread central nervous system metastases and died within 2 years of diagnosis, the remaining four patients are still alive and show no signs of recurrent disease, with the exception of patient 21.
In addition to tabulated mutations, a silent, G to A transversion at nucleotide position 1292 accompanied by a loss of the wild-type allele was found in patient PM1 and a C to T transition was revealed in position 722 of the 3' splice site of intron 5, possibly representing a previously undescribed rare polymorphism ( Figure 1e ). This single constitutional alteration was not found by analysing more than 80 individuals of Northern European ancestry. None of the mutations described in this study were previously observed in patients with NBCCS. No mutation was found in the cell lines included in the study. Wild-type alleles were absent in most tumours with mutations ( Figures 1 and 2a) , indicating either LOH in tumours or absence of mutations in the germ-line.
Somatic origin of mutations
In order to address the origin of the identi®ed mutations, normal DNA samples from patients with PNETs were analysed in parallel with mutated tumour DNA. These results showed that, with the exception of the intron 5 alteration (Figure 1e and text above), none of the mutations were present in the germ-line, providing evidence for their clonal, somatic origin.
PTCH mutations occur predominantly in PNETs with LOH at 9q LOH in at least one locus around PTCH was detected in altogether six of 31 tumour blood pairs examined (Table 1) . Interestingly, LOH at the NBCCS locus and anking markers was found in at least three out of ®ve tumours exhibiting PTCH mutation, but only in three of 26 analysed tumour samples in which a mutation was not detected. This indicates that PTCH mutations occur more frequently in PNETs with LOH at 9q22-q23 than in tumours retaining both alleles. This bias in the distribution of mutation-containing tumours towards those with LOH implicates PTCH as the target gene in PNETs with LOH at 9q22-q23 and, together with the presence of loss-of-function mutations in at least 13% of sporadic tumours, suggests the causal role of de®cient PTCH in the development of this subset of PNETs.
In tumour DNA samples exhibiting LOH, there was no instance of retention of heterozygosity in any of the loci examined, strongly suggesting the absence of large genomic regions of a genetic distance of at least 27 cM involving the PTCH locus (data not shown).
Discussion
In this study, we provide evidence for pleiotropic involvement of an important skin cancer gene in tumours originating from a dierent tissue by demonstrating mutations that are predicted to lead to a de®cient shh receptor PTCH in PNETs. Other tumour suppressors such as the p53 or retinoblastoma gene products have previously been shown to exhibit mutations in a variety of tumours (Weinberg, 1995; Ko and Pirves, 1996) . Although p53 was suggested as a tumour suppressor de®cient in PNETs exhibiting frequent LOH at 17p (Cogen et al., 1992; Scheurlen et al., 1997) , the frequency of tumours with p53 mutations does not appear to exceed 5% (Saylors III et al., 1991 ± 0/12 tumours and 1/3 permanent cell lines; Badiali et al., 1993 ± 2/22; Scheurlen et al., 1997 ± 0/10). Despite the facts that the p53 gene was often incompletely analysed and the sensitivity of mutation screening is suboptimal, a preliminary comparison suggests that the proportion of PNETs with PTCH mutations is higher than that with a mutation in p53.
It is also possible that PTCH may be mutated in other tumours, particularly of ectodermal origin. Recent mutation analysis of 14 squamous cell carcinomas (Ecklund et al., submitted) and 20 transitional cell carcinomas of the urinary bladder (Simoneau et al., 1996) failed to demonstrate any mutations. Our analysis of two patients with the Ferguson-Smith syndrome, a rare hereditary disease characterized by multiple self-healing epitheliomata (MIM 132800) mapped to a region closely linked to the NBCCS locus (Goudie et al., 1993) , also failed to show any PTCH mutations, suggesting that the underlying gene is dierent from PTCH (VorÏ echovskyÂ et al., unpublished data). Johnson et al. (1996) (GenBank accession number U59464); b LOH was shown both by PCR-SSCP and¯anking microsatellite markers as described in Materials and methods section. Only informative markers are listed. ND, not determined. Note: The designation of mutations is according to recommended nomenclature (Beaudet, 1996) . The data were submitted to the locus-speci®c mutation database at http://www.sics.se/ktm/projects/PTCH/ A signi®cantly increased risk for the development of medulloblastomas has been reported for patients with the Turcot's syndrome, associated with germ-line mutations in the APC tumour suppressor gene (Hamilton et al., 1995) . However, no APC mutations have so far been found in sporadic PNETs (Mori et al., 1994) , nor have LOH at the APC locus been observed in such tumours (Yong et al., 1995) . Both PTCH and APC are involved in interdependent signalling pathways important for normal brain development and neuronal cell fate determination (Hammerschmidt et al., 1997; Bhat et al., 1996) .
Even though medulloblastomas occur only in about 3 ± 5% of patients with NBCCS (Evans et al., 1991 (Evans et al., , 1993 , they have been proposed to represent a diagnostic criterion of the syndrome. In theory, this tumour might manifest early in childhood as the ®rst observed NBCCS symptom. Since patients with PNETs have short survival, it may also be the last symptom in an NBCCS patient. However, the hypothesis that inactivating germ-line PTCH mutations confer a signi®cant risk to sporadic PNETs does not appear to be supported by our study. Similarly, Evans et al. (1991) assessed case notes of 173 consecutive medulloblastomas and found only two patients complying with the diagnostic criteria of NBCCS, while excluding NBCCS in the majority of patients. The absence of germ-line mutations in our series of tumours is consistent with the view that medulloblastomas manifesting as the ®rst feature of the Gorlin syndrome would be, despite of somewhat lower than expected mutation detection rate in NBCCS families (Wicking et al., 1997; VorÏ echovskyÂ et al., unpublished data) rare.
Although medulloblastomas in patients with NBCCS seem to manifest earlier in life than in general population (Lacombe et al., 1990) , the age of onset in our patients with PTCH mutations does not appear to be biased (Tables 1 and 2 ). Selection of a larger set of patients with medulloblastomas starting during the ®rst years of life for mutation studies of this gene might help resolve this issue.
The proportion of tumours with LOH at 9q found in this study is comparable to previous data, reporting LOH at this region in two out of 15 sporadic medulloblastomas (Albrecht et al., 1994) , in three of 24 medulloblastomas (Scheurlen et al., 1997) and in three of 17 PNETs (Scho®eld et al. 1995) . The latter study suggested that LOH occurred preferentially in desmoplastic medulloblastomas, rare variants of PNETs, which appear to be more common in NBCCS. Scheurlen et al. (1997) found LOH in one of ®ve desmoplastic medulloblastomas using marker D9S277. In our study, the analysis of a single desmoplastic tumour (patient 22321 in Table 1 ) did not reveal any PTCH mutation.
In summary, we have demonstrated somatic mutations in the human homologue of Drosophila patched in PNETs. Mutations would be predicted to result in de®cient PTCH and SHH signalling. We have also shown that the PTCH gene is predominantly mutated in tumours exhibiting LOH at 9q22-q23, consistent with the important role of this tumour suppressor in the development of a subset of PNETs. The absence of mutations in the germ-line supports the view that the development of medulloblastomas as the ®rst feature of NBCCS is uncommon. 
Materials and methods
Tumour samples
A total of 37 tumour samples from unrelated Swedish patients with PNETs were studied. The samples were obtained from the Karolinska and Uppsala University Hospitals. The mean age of patients at diagnosis was 12 years, ranging between half and 81 years (median 8 years). The patients and tumours are described in Table 1 . Histopathological criteria for PNETs were according to the WHO recommendations (Kleihus and Burger, 1993) . Histopathological evaluation of each tumour sample was carried out to ensure that the material contained at least 85% tumour cells. Apart from surgically removed tumours, DNA from ®ve medulloblastoma cell lines were also analysed: PFSK1, D283Med, D324Med, D341Med and D425Med (Fults et al., 1992; Friedman et al., 1985 Friedman et al., , 1988 He et al., 1991) . PFSK1 was purchased from the ATCC, the remaining cell lines were kindly provided by Dr DD Bigner, Duke University, Durham, USA.
Nucleic acid extraction
DNA was extracted using the Wizard 2 Genomic DNA Puri®cation Kit (Promega) or a conventional phenol/ chlorophorm extraction method. Tumour DNA samples were isolated from fresh tumour tissues stored at 71358C before extraction. RNA extraction and the ®rst-strand cDNA synthesis was performed as previously described (VorÏ echovskyÂ et al., 1994) .
Microsatellite analysis
The following polymorphic markers were used at 9q (ordered from centromere to telomere): D9S152, D9S197, D9S196, (NBCCS, D9S287) and D9S277 (Research Genetics, Huntsville, AL). The estimated genetic distances between the markers were 18, 0, 2 and 7 cM, respectively (Dib et al., 1996) . Fifty ng of genomic DNA was ampli®ed in a volume of 10 ml containing 10 mM Tris-HCl, 50 mM KCl, 1.0 ± 2.0 mM MgCl 2 12.5 mM of each dNTPs, 0.5 mCi of [a-33 P]dCTP and 0.25 units of Taq polymerase (Perkin Elmer). The concentrations of Mg 2+ ions, annealling temperatures and the number of cycles were optimized for each primer pair to obtain consistent results with a minimum number of cycles. PCR products were electrophoresed on 4.5 ± 6% denaturing polyacrylamide gels, dried and exposed to a storage phosphor screen. The screens were analysed using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) and ImageQuant software. Loss of heterozygosity in the tumour DNA was determined by a comparison of the densitometric curves obtained from the digitalised signal from normal and tumour DNA at each locus.
PCR ± SSCP analysis and sequencing
The sequences of oligonucleotide primers used for PCR ± SSCP were as described previously (Hahn et al., 1996b; Unden et al., 1996) . PCR reactions contained 100 ng DNA, 0.25 mM of each primer, 100 mM of each dNTP, 1.5 mM MgCl 2 , 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.01% gelatin, 0.2 mCi [a-32 P]dCTP (3000 Ci/mmol) and 0.5 units of Taq polymerase (Perkin-Elmer) in a volume of 20 ml. Ampli®cations were for 30 ± 35 cycles at 948C for 30 s, annealing at 52 ± 588C for 45 s and extension at 728C for 30 s in a Perkin-Elmer thermocycler (GeneAmp System 9600). The samples were mixed with 95% formamide, 0.05% bromophenol blue, 0.05% xylene cyanol, 50 mM NaOH, denatured at 958C for 10 min and loaded onto 0.4 mm/30 cm/45 cm 5% polyacrylamide/5% glycerol gels (crosslinking 2.5%). The electrophoresis was conducted at 2 ± 5 W at room temperature overnight. The gels were dried and autoradiographed for 1 ± 2 days at 7708C. PTCH segments identi®ed to contain mutations were re-ampli®ed together with the negative and positive controls, using both cut fragments exhibiting bandshifts and original DNA samples as described . DNA was sequenced in both directions using cycle sequencing with AmpliTaqFS (Perkin Elmer) on the ABI 373A DNA sequencer.
